Understanding and maximising the community impact of seasonal malaria chemoprevention in Burkina Faso (INDIE-SMC): study protocol for a cluster randomised evaluation trial

Understanding and maximising the community impact of seasonal malaria chemoprevention in Burkina Faso (INDIE-SMC): study protocol for a cluster randomised evaluation trial

Introduction Seasonal malaria chemoprevention (SMC) involves repeated administrations of sulfadoxine-pyrimethamine plus amodiaquine to children below the age of 5 years during the peak transmission season in areas of seasonal malaria transmission. While highly impactful in reducing Plasmodium falcip...

Full description

Bibliographic Details
Main Authors:	John Bradley, Alphonse Ouedraogo, Issiaka Soulama, Chris Drakeley, Teun Bousema, Alfred B Tiono, Denise Hien, Sodiomon Bienvenu Sirima, Issa N Ouedraogo, Jean Baptist Yaro, Aïssata Barry, Seyi Soremekun, Marta Moreno, Jean Sawadogo, Markus Gmeiner, Samuel S Sermé, Isabel Byrne, Jordache Ramjith, Lynn Grignard, Simon Koele, Rob ter Heine, Amidou Z Ouedraogo, Edith Sanogo
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/14/3/e081682.full

Similar Items

Seasonal performance of a malaria rapid diagnosis test at community health clinics in a malaria-hyperendemic region of Burkina Faso
by: Diarra Amidou, et al.
Published: (2012-05-01)

Contribution of the Rapid LAMP-Based Diagnostic Test (RLDT) to the Evaluation of Enterotoxigenic <i>Escherichia coli</i> (ETEC) and <i>Shigella</i> in Childhood Diarrhea in the Peri-Urban Area of Ouagadougou, Burkina Faso
by: Alimatou Héma, et al.
Published: (2023-11-01)

Variation in haematological parameters in children less than five years of age with asymptomatic Plasmodium infection: implication for malaria field studies
by: Adama Gansane, et al.
Published: (2013-08-01)

Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
by: Amadou T Konaté, et al.
Published: (2011-02-01)

Risk factors for Plasmodium falciparum infection in pregnant women in Burkina Faso: a community-based cross-sectional survey
by: Jean Baptiste Yaro, et al.
Published: (2021-09-01)

Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso
by: Diarra Amidou, et al.
Published: (2012-03-01)

Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.
by: Amadou T Konaté, et al.
Published: (2011-01-01)

Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso.
by: Alphonse Ouédraogo, et al.
Published: (2013-01-01)

Haemoglobin variants and <it>Plasmodium falciparum</it> malaria in children under five years of age living in a high and seasonal malaria transmission area of Burkina Faso
by: Bougouma Edith C, et al.
Published: (2012-05-01)

Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children
by: Edith Christiane Bougouma, et al.
Published: (2022-08-01)

Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).
by: David Tiga Kangoye, et al.
Published: (2014-01-01)

Higher gametocyte production and mosquito infectivity in chronic compared to incident Plasmodium falciparum infections
by: Aissata Barry, et al.
Published: (2021-04-01)

Hospital-based surveillance of severe paediatric malaria in two malaria transmission ecological zones of Burkina Faso
by: Alfred B. Tiono, et al.
Published: (2023-01-01)

Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
by: Sodiomon B Sirima, et al.
Published: (2009-10-01)

Correction: Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children.
by: Sodiomon B. Sirima, et al.
Published: (2010-01-01)

Malariometric Indices in the Context of Seasonal Malaria Chemoprevention in Children Aged 1.5 to 12 Years during the Period of High Malaria Transmission in the Suburban Area of Banfora, Burkina Faso
by: San M. Ouattara, et al.
Published: (2023-09-01)

Quantifying Reductions in Plasmodium falciparum Infectivity to Mosquitos: A Sample Size Calculator to Inform Clinical Trials on Transmission-Reducing Interventions
by: Jordache Ramjith, et al.
Published: (2022-06-01)

Functional antibodies against Plasmodium falciparum sporozoites are associated with a longer time to qPCR-detected infection among schoolchildren in Burkina Faso [version 2; peer review: 1 approved, 2 approved with reservations]
by: Aissata Barry, et al.
Published: (2019-05-01)

Functional antibodies against Plasmodium falciparum sporozoites are associated with a longer time to qPCR-detected infection among schoolchildren in Burkina Faso [version 1; referees: 1 approved, 2 approved with reservations]
by: Aissata Barry, et al.
Published: (2018-12-01)

Flexible time-to-event models for double-interval-censored infectious disease data with clearance of the infection as a competing risk
by: Jordache Ramjith, et al.
Published: (2022-11-01)

Impact of Plasmodium falciparum infection on DNA methylation of circulating immune cells
by: Dareen Almojil, et al.
Published: (2023-07-01)

Seasonal Malaria Chemoprevention Implementation: Effect on Malaria Incidence and Immunity in a Context of Expansion of P. falciparum Resistant Genotypes with Potential Reduction of the Effectiveness in Sub-Saharan Africa
by: Nikiema S, et al.
Published: (2022-08-01)

The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated <it>Plasmodium falciparum</it>
by: Kiechel Jean, et al.
Published: (2009-03-01)

Risk of Plasmodium falciparum infection in south-west Burkina Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention
by: Jean Baptiste Yaro, et al.
Published: (2022-01-01)

Different approaches for delivery of Intermittent Preventive Treatment (IPT) to pregnant women in Burkina Faso
by: Traoré Abdoulaye, et al.
Published: (2010-10-01)

Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods.
by: Alfred B Tiono, et al.
Published: (2014-01-01)

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.
by: Alphonse Ouédraogo, et al.
Published: (2013-01-01)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
by: Alfred B Tiono, et al.
Published: (2018-01-01)

Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso
by: Sodiomon B. Sirima, et al.
Published: (2021-01-01)

Haematological parameters, natural regulatory CD4 + CD25 + FOXP3+ T cells and γδ T cells among two sympatric ethnic groups having different susceptibility to malaria in Burkina Faso
by: Sanou Guillaume S, et al.
Published: (2012-01-01)

Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP)
by: Kangoye, D, et al.
Published: (2014)

Integrative genomic analysis reveals mechanisms of immune evasion in P. falciparum malaria
by: Mame Massar Dieng, et al.
Published: (2020-10-01)

Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
by: Alphonse Ouédraogo, et al.
Published: (2023-10-01)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
by: Richard Morter, et al.
Published: (2022-12-01)

Analyse des phénomènes sociolinguistiques dans les chansons du groupe humoristique Les séparables du Burkina Faso
by: Sobzanga Edouard SAWADOGO & Jean-Paul OUEDRAOGO
Published: (2022-12-01)

Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso
by: Mariama K. Cherif, et al.
Published: (2017-09-01)

Genotype Analysis of Clinical Candida albicans Isolates Using PCRs Targeting 25S rDNA and ALT Repeat Sequences of the RPS and Antifungal Susceptibility in Ouagadougou (Burkina Faso)
by: Sawadogo PM, et al.
Published: (2019-12-01)

Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso
by: Denise Hien, et al.
Published: (2022-06-01)

Factors Influencing Second and Third Dose Observance during Seasonal Malaria Chemoprevention (SMC): A Quantitative Study in Burkina Faso, Mali and Niger
by: Anyirékun Fabrice Somé, et al.
Published: (2022-08-01)

Feasibility and Acceptability of a Strategy Deploying Multiple First-Line Artemisinin-Based Combination Therapies for Uncomplicated Malaria in the Health District of Kaya, Burkina Faso
by: Jean Moïse Tanga Kaboré, et al.
Published: (2023-03-01)